Top

Published in:

01-11-2016 | Original Article

Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6/STAT3 signaling pathway

Authors: Wanjing Shen, Yanyan Yuan, Ming Zhao, Jiahui Li, Jin Xu, Guoying Lou, Jiachen Zheng, Shizhong Bu, Junming Guo, Yang Xi

Published in: Tumor Biology | Issue 11/2016

Abstract

Long non-coding RNAs (lncRNAs) play an important role in cancer occurrence and development. We previously demonstrated that lncRNA gastric cancer-associated transcript 3 (GACAT3) was positively correlated with TNM stages, tumor size, and distant metastasis of patients with gastric cancer. However, the role of GACAT3 in gastric cancer remains unclear. In this study, to investigate its function, we synthesized small interference RNAs (siRNAs) against GACTA3 and developed a GACAT3 overexpression vector (pcDNA3-GACAT3), respectively. The siRNA-mediated knockdown of GACAT3 significantly decreased cell proliferation of the gastric cancer HGC-27 cells, in which GACAT3 is overexpressed. Furthermore, GACAT3 overexpression in gastric cancer SGC-7901 cells promoted cell growth. Moreover, GACAT3 expression in HGC-27 cells was greatly upregulated by IL-6 treatment in a concentration-dependent manner. In contrast, siRNA-mediated knockdown of STAT3 decreased GACAT3 expression even in the presence of IL-6. These results demonstrated that as a downstream target of the IL6/STAT3 signaling, lncRNA GACAT3 promotes gastric cancer cell growth suggesting that GACAT3 is an inflammatory response gene and may be served as a valuable potential target for the treatment of gastric cancer.

Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330–44.CrossRefPubMed

Wang K, Liang Q, Li X, Tsoi H, Zhang J, Wang H, et al. MDGA2 is a novel tumour suppressor cooperating with dmap1 in gastric cancer and is associated with disease outcome. Gut. 2015. doi:10.1136/gutjnl-2015-309276.

Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer. 2004;7:9–16.CrossRefPubMed

Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Cancer Netw. 2010;8:437–47.

Stewart BW, Wild CP, editors. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014. p. 2014.

Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20:1635–49.CrossRefPubMedPubMedCentral

Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed

Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354–61.CrossRefPubMed

Xie SS, Jin J, Xu X, Zhuo W, Zhou TH. Emerging roles of non-coding rnas in gastric cancer: pathogenesis and clinical implications. World J Gastroenterol. 2016;22:1213–23.CrossRefPubMedPubMedCentral

10.

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.CrossRefPubMed

11.

Song H, Sun W, Ye G, Ding X, Liu Z, Zhang S, et al. Long non-coding rna expression profile in human gastric cancer and its clinical significances. J Transl Med. 2013;11:225.CrossRefPubMedPubMedCentral

12.

Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y, et al. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep. 2014;4:6088.PubMedPubMedCentral

13.

Chen S, Li P, Xiao B, Guo J. Long noncoding RNA hmlincrna717 and ac130710 have been officially named as gastric cancer associated transcript 2 (gacat2) and gacat3, respectively. Tumor Biol. 2014;35:8351–2.CrossRef

14.

Xu C, Shao Y, Xia T, Yang Y, Dai J, Luo L, et al. Lncrna-ac130710 targeting by mir-129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumor Biol. 2014;35:9701–6.CrossRef

15.

Yu X, Song H, Xia T, Han S, Xiao B, Luo L, et al. Growth inhibitory effects of three mir-129 family members on gastric cancer. Gene. 2013;532:87–93.CrossRefPubMed

16.

Madej-Michniewicz A, Budkowska M, Salata D, Dolegowska B, Starzynska T, Blogowski W. Evaluation of selected interleukins in patients with different gastric neoplasms: a preliminary report. Sci Rep. 2015;5:14382.CrossRefPubMedPubMedCentral

17.

Eiro N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg. 2012;4:62–72.CrossRefPubMedPubMedCentral

18.

Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009;1171:59–76.CrossRefPubMedPubMedCentral

19.

Yu H, Pardoll D, Jove RSTAT. In cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.CrossRefPubMedPubMedCentral

20.

Frank DA. Stat signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat Res. 2003;115:267–91.CrossRefPubMed

21.

Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, et al. Stat3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004;23:4921–9.CrossRefPubMed

22.

Hajimoradi M, Mohammad Hassan Z, Ebrahimi M, Soleimani M, Bakhshi M, Firouzi J, et al. STAT3 is overactivated in gastric cancer stem-like cells. Cell J. 2016;17:617–28.PubMedPubMedCentral

23.

Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2015;125:1362.CrossRefPubMedPubMedCentral

24.

Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014;44:403–11.PubMed

25.

Xi Y, Watanabe S, Hino Y, Sakamoto C, Nakatsu Y, Okada S, et al. Hmga1 is differentially expressed and mediates silencing of the CD4/CD8 loci in T cell lineages and leukemic cells. Cancer Sci. 2012;103:439–47.CrossRefPubMed

26.

Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.CrossRefPubMed

27.

Zhao J, Liu Y, Huang G, Cui P, Zhang W, Zhang Y. Long non-coding RNAs in gastric cancer: versatile mechanisms and potential for clinical translation. Am J Cancer Res. 2015;5:907–27.PubMedPubMedCentral

28.

Lu MH, Tang B, Zeng S, Hu CJ, Xie R, Wu YY, et al. Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. Oncogene. 2015. doi:10.1038/onc.2015.413.

29.

Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, et al. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J. 2014;281:802–13.CrossRefPubMed

30.

Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y, et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS One. 2013;8:e75788.CrossRefPubMedPubMedCentral

31.

Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, et al. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One. 2014;9:e95993.CrossRefPubMedPubMedCentral

32.

Zhong Z, Wen Z, Darnell Jr JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95–8.CrossRefPubMed

33.

Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62:3351–5.PubMed

34.

Gortz D, Braun GS, Maruta Y, Djudjaj S, van Roeyen CR, Martin IV, et al. Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. Sci Rep. 2015;5:14685.CrossRefPubMedPubMedCentral

Title: Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6/STAT3 signaling pathway
Authors: Wanjing Shen
Yanyan Yuan
Ming Zhao
Jiahui Li
Jin Xu
Guoying Lou
Jiachen Zheng
Shizhong Bu
Junming Guo
Yang Xi
Publication date: 01-11-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5372-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Creation of an apoptin-derived peptide that interacts with SH3 domains and inhibits glioma cell migration and invasion

RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC

MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition

Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer

High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma

Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer